Open Access

Using the polymeric circulating tumor cell chip to capture circulating tumor cells in blood samples of patients with colorectal cancer

  • Authors:
    • Kazumasa Kure
    • Masaki Hosoya
    • Takae Ueyama
    • Midori Fukaya
    • Kiichi Sugimoto
    • Yuichi Tomiki
    • Takashi Ohnaga
    • Kazuhiro Sakamoto
    • Hiromitsu Komiyama
  • View Affiliations

  • Published online on: January 23, 2020     https://doi.org/10.3892/ol.2020.11335
  • Pages: 2286-2294
  • Copyright: © Kure et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The current study clarified the accuracy of a circulating tumor cell (CTC) detection system to diagnose colorectal cancer using blood samples. The system uses the ‘polymeric CTC‑chip,’ (CTC‑chip), which is a microfluidic device that is used for CTC isolation. CTCs are considered sensitive diagnostic biomarkers. However, their concentration in the peripheral blood is low and requires highly sensitive and specific capturing techniques. The capture efficiency of the polymeric CTC‑chip was first assessed using cell suspensions of the colorectal cancer cell line HCT‑116, which was reported as 90.9% in a phosphate‑buffered saline suspension and 65.0% in the blood. The CTC‑chip was then used to detect CTCs in blood samples obtained from 13 patients with stage II‑IV colorectal cancer. On average, the CTCs/ml was lower in patients with stages II and III colorectal cancer (3.3±2.3) than in those with stage IV (7.0±6.2). In patients with stages II‑IV, 92% had ≥1 CTC per ml, which was significantly higher than the positive rate (15%) detected using the carbohydrate antigen 19‑9 test (CA19‑9). Furthermore, CTCs were detected in all patients with stage II and III colorectal cancer, including a number of patients with negative results for the carcinoembryonic antigen (CEA) and CA19‑9 tests. With the polymeric CTC‑chip detection system, CTCs can be effective cancer markers, particularly for patients with stage II and III colorectal cancer who often exhibit negative conventional serum marker test results. The CTC‑chip system may also facilitate the detection of cancer progression based on CTC concentration.

Related Articles

Journal Cover

March 2020
Volume 19 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Kure, K., Hosoya, M., Ueyama, T., Fukaya, M., Sugimoto, K., Tomiki, Y. ... Komiyama, H. (2020). Using the polymeric circulating tumor cell chip to capture circulating tumor cells in blood samples of patients with colorectal cancer. Oncology Letters, 19, 2286-2294. https://doi.org/10.3892/ol.2020.11335
MLA
Kure, K., Hosoya, M., Ueyama, T., Fukaya, M., Sugimoto, K., Tomiki, Y., Ohnaga, T., Sakamoto, K., Komiyama, H."Using the polymeric circulating tumor cell chip to capture circulating tumor cells in blood samples of patients with colorectal cancer". Oncology Letters 19.3 (2020): 2286-2294.
Chicago
Kure, K., Hosoya, M., Ueyama, T., Fukaya, M., Sugimoto, K., Tomiki, Y., Ohnaga, T., Sakamoto, K., Komiyama, H."Using the polymeric circulating tumor cell chip to capture circulating tumor cells in blood samples of patients with colorectal cancer". Oncology Letters 19, no. 3 (2020): 2286-2294. https://doi.org/10.3892/ol.2020.11335